Previous 10 | Next 10 |
Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of strategic business development executive Courtney Wallace to its Board ...
Shares of Kezar Life Sciences Inc. (NASDAQ:KZR) traded today at $15.62, eclipsing its 52-week high. So far today approximately 3.3 million shares have been exchanged, as compared to an average 30-day volume of 2.4 million shares. Kezar Life Sciences Inc. share prices have moved between a...
On a day that saw the release of better-than-expected retail sales and modest gains on Wall Street, a very specific part of the retailing sector moved into the spotlight on Tuesday. Bolstered by strong earnings from Home Depot, shopping outlets focused on housing products rallied. Lowe's (NYS...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Kezar Life Sciences Inc. Announces Interim Results from the MISSION Phase 2 Trial” Kezar Life Sciences Inc. (NASDAQ: KZR) surged over 42% in premarket trading afte...
Gainers: BIMI International Medical (NASDAQ:BIMI) +55%. Kezar Life Sciences (NASDAQ:KZR) +31%. CNS Pharmaceuticals (NASDAQ:CNSP) +28%. ReTo Eco-Solutions (NASDAQ:RETO) +28%. Progenity (NASDAQ:PROG) +27%. PLBY Group (NASDAQ:PLBY) +27%. IonQ (NYSE:IONQ) +25%. Kuke (NYSE:KUKE) +21%. On Holding (...
Shares of Kezar Life Sciences (NASDAQ: KZR) were soaring 36.1% as of 11:03 a.m. EST on Tuesday. The big gain came after the company announced interim results on Monday from a phase 2 study evaluating KZR-616 in treating autoimmune disease lupus nephritis. With the huge move for ...
Gainers: Kezar Life Sciences KZR +36%, Progenity (NASDAQ:PROG) +28%, GeoVax Labs GOVX +15%, Medicenna Therapeutics (NASDAQ:MDNA) +15%, Amarin AMRN +10%. Losers: Talkspace TALK -37%, OptiNose OPTN -34%, Molecular Partners MOLN...
The shares of Kezar Life Sciences (KZR +36.6%) have approached a 52-week high after the company reported encouraging mid-stage interim data for its lupus nephritis (LN) therapy KZR-616. Wall Street analysts have cheered the results, which, according to Kezar’s (NASDAQ:KZR) Chief M...
Kezar Life Sciences (NASDAQ:KZR) +46% on phase 2 data for lupus candidate Axon Enterprise (NASDAQ:AXON) +24% on Q3 results Cyclo Therapeutics (NASDAQ:CYTH) +19% on Q3 results. Comstock Holding Companies (NASDAQ:CHCI) +20% on Q3 results. Romeo Power (NYS...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday. Source: f11photo/Shutterstock.com There’s loads of earning reports out today, as wel...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...